The pharmacogenomics of selective serotonin reuptake inhibitors.

摘要: The introduction of selective serotonin (5-HT) reuptake inhibitors (SSRIs) has significantly improved the pharmacological treatment a range psychiatric disorders. Nevertheless, despite undoubted advantages antidepressant in terms tolerability to therapy while maintaining high level efficacy, not all patients benefit from it; an appreciable proportion do respond adequately, others may show adverse reactions. necessary change initial choice often requires extended periods for remission symptomatology. Such difficulties could be avoided if it should possible determine more quickly most suitable drug. Several factors have been thought influence outcome therapy. Among influencing interindividual variability response with SSRI, differences genetic features play significant role. polymorphisms associated therapeutic SSRI response, including variants 5-HT transporter, 5-HT-2A-receptor, tryptophan hydroxylase, brain-derived neurotrophic factor, G-protein beta3 subunit, interleukin-1beta and angiotensin-converting enzyme, although conflicting results; also cytochrome P450 drug-metabolising enzymes bear particular importance, further corroboration findings is necessary, key participating genes remain identified. hope that identification these components will eventually facilitate development customised treatment.